NASDAQ: $MTVA Metavia, Inc., a company focused on novel therapeutic development, recently announced encouraging results stemming from its ongoing artificial intelligence (AI) modeling collaboration with Syntekabio. These latest findings solidify key therapeutic targets relevant to their lead compound, Vanoglipel, a promising drug candidate. The collaboration leverages Syntekabio’s advanced AI platforms to expedite and refine the…